John P. McLaughlin
Mr. McLaughlin joined the PDL BioPharma Board of Directors in October 2008. Mr. McLaughlin served as Chief Executive Officer of PDL BioPharma from 2008 to 2018 and was also the Company’s President from 2008 to 2017.
Prior to joining PDL, he was Chief Executive Officer and Director of Anesiva, Inc. (formerly Corgentech, Inc.) from 2000 to 2008 and President of Tularik, Inc. from 1997 to 1999. Prior to that, Mr. McLaughlin held various senior management positions at Genentech, Inc. from 1987 to 1997, including Executive Vice President and General Counsel. From 1985 to 1987, Mr. McLaughlin was a partner at a Washington, D.C.-based law firm specializing in food and drug law. Previously, Mr. McLaughlin served as counsel to various subcommittees of the United States House of Representatives, where he drafted numerous measures that became FDA laws. He holds a B.A. from the University of Notre Dame and a J.D. from Catholic University of America.
Mr. McLaughlin co-founded and served as Chairman of the Board of Directors of Eyetech Pharmaceuticals, Inc., and co-founded and served as Director of Peak Surgical, Inc., with both firms subsequently acquired by OSI Pharmaceuticals and Medtronic, respectively. He previously served as a Director of AxoGen, Inc., Adverum Biotechnologies, Inc. and Seattle Genetics, Inc. He serves on the Board of Directors of PDL’s subsidiaries, Noden Pharma DAC and LENSAR.
Mr. McLaughlin brings the Board of Directors of PDL BioPharma a strong understanding of the biotechnology industry and experience in the development, regulation and commercialization of drugs, as well as corporate licensing and litigation. He is a member of the Litigation Committee.